Header Logo

Connection

WOLFGANG WINKELMAYER to Anemia

Back to Details
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Anemia.
WOLFGANG WINKELMAYER
Connection Strength
7.697
Anemia
  1. Cardiovascular Safety of Roxadustat in CKD Anemia: A Fig Leaf Named Noninferiority. Clin J Am Soc Nephrol. 2021 08; 16(8):1155-1157.
    View in: PubMed
    Score: 0.569
  2. Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex. Am J Kidney Dis. 2017 Jun; 69(6):771-779.
    View in: PubMed
    Score: 0.414
  3. The Dawning of a New Day in CKD Anemia Care? J Am Soc Nephrol. 2016 Apr; 27(4):968-70.
    View in: PubMed
    Score: 0.381
  4. Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients. Nephrol Dial Transplant. 2015 Dec; 30(12):2068-75.
    View in: PubMed
    Score: 0.377
  5. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med. 2014 May; 174(5):699-707.
    View in: PubMed
    Score: 0.344
  6. Commentary on 'The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle': iron(y) abounds 2 years later. Am J Kidney Dis. 2013 Dec; 62(6):1217-20.
    View in: PubMed
    Score: 0.334
  7. Commentary on 'The DOPPS Practice Monitor for US dialysis care: trends through December 2011': results from year one. Am J Kidney Dis. 2013 Feb; 61(2):346-8.
    View in: PubMed
    Score: 0.316
  8. What caused excess strokes in patients randomized to darbepoetin in the trial to reduce cardiovascular events with Aranesp therapy (TREAT)?: no smoking gun. Circulation. 2011 Dec 20; 124(25):2805-8.
    View in: PubMed
    Score: 0.292
  9. Posttransplantation anemia: mechanisms and management. Clin J Am Soc Nephrol. 2011 Jul; 6(7):1794-801.
    View in: PubMed
    Score: 0.283
  10. The effect of altitude change on anemia treatment response in hemodialysis patients. Am J Epidemiol. 2011 Apr 01; 173(7):768-77.
    View in: PubMed
    Score: 0.276
  11. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting. J Am Soc Nephrol. 2011 Jan; 22(1):1-2.
    View in: PubMed
    Score: 0.272
  12. The challenges of cost-effectiveness analyses for the clinician. Am J Kidney Dis. 2010 Dec; 56(6):1023-5.
    View in: PubMed
    Score: 0.271
  13. Confusion about the appropriate use of erythropoiesis-stimulating agents in patients undergoing maintenance dialysis. Semin Dial. 2010 Sep-Oct; 23(5):486-91.
    View in: PubMed
    Score: 0.267
  14. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA. 2010 Mar 03; 303(9):857-64.
    View in: PubMed
    Score: 0.258
  15. The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol. 2008 Jul; 19(7):1389-95.
    View in: PubMed
    Score: 0.226
  16. Pottransplantation anemia: management and rationale. Clin J Am Soc Nephrol. 2008 Mar; 3 Suppl 2:S49-55.
    View in: PubMed
    Score: 0.224
  17. A prospective study of anaemia and long-term outcomes in kidney transplant recipients. Nephrol Dial Transplant. 2006 Dec; 21(12):3559-66.
    View in: PubMed
    Score: 0.204
  18. Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol. 2004 May; 15(5):1347-52.
    View in: PubMed
    Score: 0.172
  19. Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. Nephrol Dial Transplant. 2023 09 29; 38(10):2358-2367.
    View in: PubMed
    Score: 0.165
  20. Market Competition and Anemia Management in the United States Following Dialysis Payment Reform. Med Care. 2023 Nov 01; 61(11):787-795.
    View in: PubMed
    Score: 0.165
  21. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023 10; 104(4):655-680.
    View in: PubMed
    Score: 0.161
  22. Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials. Am J Nephrol. 2022; 53(10):701-710.
    View in: PubMed
    Score: 0.156
  23. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Am J Hematol. 2022 09; 97(9):1178-1188.
    View in: PubMed
    Score: 0.152
  24. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrol Dial Transplant. 2021 11 09; 36(11):2039-2048.
    View in: PubMed
    Score: 0.145
  25. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021 04 29; 384(17):1589-1600.
    View in: PubMed
    Score: 0.140
  26. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 04 29; 384(17):1601-1612.
    View in: PubMed
    Score: 0.140
  27. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int. 2021 06; 99(6):1280-1295.
    View in: PubMed
    Score: 0.139
  28. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. Am Heart J. 2021 05; 235:1-11.
    View in: PubMed
    Score: 0.135
  29. [Hospitalization and Critical Illness in Chronic Kidney Disease]. Cardiorenal Med. 2020; 10(5):302-312.
    View in: PubMed
    Score: 0.130
  30. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J Med Econ. 2019 Jun; 22(6):593-604.
    View in: PubMed
    Score: 0.121
  31. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis. 2015 Jul; 66(1):106-13.
    View in: PubMed
    Score: 0.092
  32. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis. 2015 Jul; 66(1):69-74.
    View in: PubMed
    Score: 0.091
  33. The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients. Am J Med. 2013 Jun; 126(6):541.e1-541.e14.
    View in: PubMed
    Score: 0.080
  34. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf. 2009 Oct; 18(10):932-40.
    View in: PubMed
    Score: 0.063
  35. No associations between prolactin concentrations and response to erythropoiesis-stimulating agents in hemodialysis patients. Am J Nephrol. 2007; 27(4):390-6.
    View in: PubMed
    Score: 0.053
  36. Anaemia after renal transplantation. Eur J Clin Invest. 2005 Dec; 35 Suppl 3:89-94.
    View in: PubMed
    Score: 0.048
  37. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004 Oct; 66(4):1712; author reply 1712-3.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.